Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
soblidotin + gemcitabine
- Development stage
- Phase 1
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Soblidotin + gemcitabine is an experimental combination chemotherapy regimen consisting of the dolastatin 10 derivative soblidotin and the nucleoside analog gemcitabine. Soblidotin (also known as TZT-1027) is a small molecule antimicrotubule agent that binds to beta-tubulin, inhibiting polymerization and inducing G2/M phase cell cycle arrest and apoptosis. Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis by acting as a nucleoside analog and inhibiting ribonucleotide reductase. The combination was investigated by Daiichi Sankyo in a Phase I clinical trial (NCT00072228) for patients with locally advanced or metastatic solid tumors. However, the trial was withdrawn before completion, and development of this specific combination has been discontinued.
- Other names
- soblidotin and gemcitabineTZT-1027 + gemcitabine
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on soblidotin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on soblidotin + gemcitabine.